DCM
CRL icon

Delaney Capital Management’s Charles River Laboratories CRL Stock Holding History

Delaney Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$983K Sell
4,335
-7,678
-64% -$1.37M 0.16% 35
2026
Q1 		$2.07M Hold
12,013
– – 0.33% 25
2025
Q4 		$2.4M Buy
+12,013
New +$2.18M 0.4% 24

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Delaney Capital Management's CRL Position: Q2 2026 in Review

Delaney Capital Management reduced its Charles River Laboratories (CRL) stake by 64% in Q2 2026, selling an estimated $1.37M and leaving 4,335 shares worth $983K. The position accounts for 0.16% of the portfolio, ranked #35.

Delaney Capital Management first reported a position in CRL in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.4M in Q4 2025. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Delaney Capital Management held 4,335 shares of Charles River Laboratories worth $983K as of Q2 2026.
  • Delaney Capital Management sold 7,678 Charles River Laboratories shares in Q2 2026, an estimated $1.37M.
  • Charles River Laboratories made up 0.16% of Delaney Capital Management's portfolio in Q2 2026, its #35 holding.
  • Delaney Capital Management first reported a position in Charles River Laboratories in Q4 2025 and has held it in 3 quarters since.
  • Delaney Capital Management's Charles River Laboratories position peaked at $2.4M in Q4 2025.
  • 563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Delaney Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.